<DOC>
	<DOCNO>NCT02431702</DOCNO>
	<brief_summary>The purpose study compare effectiveness paliperidone palmitate ( PP : paliperidone palmitate once-monthly 3-month injection ) versus oral antipsychotic ( OAP ) delay time treatment failure . The study also evaluate change cognition , functioning , brain intracortical myelin ( ICM ) volume follow treatment PP compare OAP participant recent-onset schizophrenia schizophreniform disorder .</brief_summary>
	<brief_title>A Study Compare Disease Progression Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection Oral Antipsychotics Participant 's With Recent-onset Schizophrenia Schizophreniform</brief_title>
	<detailed_description>A Prospective , matched-control , Randomized ( assignment study drug chance ) , open-label , flexible-dose , study participant recent-onset schizophrenia schizophreniform disorder compare disease progression disease modification follow treatment PP long-acting injection ( once-monthly follow 3-month injection ) OAP ( Any follow 7 OAPs permit : aripiprazole , haloperidol , olanzapine , paliperidone ER , perphenazine , quetiapine , risperidone ) . The study consist 3 part . Part-1 ( Oral Run-In Phase ) , Part-2 ( Disease Progression ) Part-3 ( Extended Disease Progression Disease Modification ) unique endpoint . Screening period 4 Weeks . Duration Parts : 2 month Part-1 , 9 month Part-2 Part-3 . All participant initially receive oral Paliperidone Extended Release ( ER ) Part-1 . After paliperidone treatment Part-1 , participant randomize 1:2 ratio receive PP OAP Part-2 . Participants complete Part-2 enter Part-3 wherein OAP group participant Part-2 re-randomized 1:1 ratio OAP-OAP group OAP-PP group , PP group continue without randomization . Treatment failure evaluate Part-2 Part-3 study . Also change cognition , functioning , brain intracortical myelin ( ICM ) volume evaluate study . Participants ' safety monitor throughout .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Perphenazine</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Participant must current diagnosis schizophrenia ( 295.90 ) schizophreniform disorder ( 295.40 ) define Diagnostic Statistical Manual Mental Disorders , 5th edition ( DSM5 ) confirm Structured Clinical Interview DSM5 Disorders ( SCID ) first psychotic episode within last 24 month Participant require treatment antipsychotic medication Participant must sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study Participant must available designate individual ( example , family member , significant , friend ) knowledge participant generally aware participant daily activity , agree let study site personnel know change participant circumstance participant able provide information . The designated individual must sign informed consent form Participant anticipate stable place residence duration trial Participant current DSM5 diagnosis dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , autistic disorder , intellectual disability Participant meet DSM5 definition moderate severe substance use disorder ( except nicotine ) within 2 month prior Screening Participant history neuroleptic malignant syndrome Participant receive longacting injectable ( LAI ) medication within 2 injection cycle prior Screening visit Participant mental retardation , define premorbid intelligence quotient ( IQ ) measure Wechsler Test Adult Reading Screening le ( &lt; ) 70</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Oral Antipsychotics</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Psychotic Disorders</keyword>
	<keyword>Cognition Schizophrenia</keyword>
	<keyword>Brain intracortical myelin volume</keyword>
	<keyword>Personal Social Performance</keyword>
	<keyword>Disease Modification</keyword>
</DOC>